



Published in final edited form as:

Semin Respir Crit Care Med. 2015 June ; 36(3): 323–333. doi:10.1055/s-0035-1547349.

Biomarkers of World Trade Center Particulate Matter Exposure: Physiology of distal airway and blood biomarkers that predict FEV₁ decline

Michael D. Weiden, MD, MS^{1,3,*}, Sophia Kwon, DO, MPH^{1,*}, Erin Caraher, BS¹, Kenneth I. Berger¹, Joan Reibman, MD¹, William N. Rom, MD^{1,2}, David J. Prezant, MD^{3,4}, and Anna Nolan, MD, MS^{1,3}

¹Division of Pulmonary, Critical Care and Sleep, New York University, School of Medicine, 462 First Avenue, NB7N24, New York, NY, 10016. (212) 263-6479

²New York University, Department of Environmental Medicine, 57 Old Forge Road, Tuxedo Park, NY, 10987. (845) 731-3500

³Bureau of Health Services and Office of Medical Affairs, Fire Department of New York, Brooklyn, NY, 212-269

⁴Pulmonary Medicine Division, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY.

Abstract

Biomarkers can be important predictors of disease severity and progression. The intense exposure to particulates and other toxins from the destruction of the World Trade Center (WTC) overwhelmed the lung's normal protective barriers. The Fire Department of New York (FDNY) cohort not only had baseline pre-exposure lung function measures but also had serum samples banked soon after their WTC exposure. This well phenotyped group of highly exposed first responders is an ideal cohort for biomarker discovery and eventual validation. Disease progression was heterogeneous in this group in that some individuals subsequently developed abnormal lung function while others recovered. Airflow obstruction predominated in WTC exposed patients who were symptomatic. Multiple independent disease pathways may cause this abnormal FEV₁ after irritant exposure. WTC exposure activates one or more of these pathways causing abnormal FEV₁ in an individual. Our hypothesis was that serum biomarkers expressed within 6 months after World Trade Center (WTC) exposure reflect active disease pathways and predict subsequent

Corresponding Author: Anna Nolan, MD, MS, Assistant Professor of Medicine and Environmental Medicine, NYU School of Medicine, Division of Pulmonary, Critical Care and Sleep, New Bellevue, 7N Room 24, 462 1st Avenue, New York, NY 10016, anna.nolan@med.nyu.edu, **Tele:** 212-263-7283; 212-562-8242, **Fax:** 212-263-8442.

michael.weiden@med.nyu.edu

sophia.kwon@nyumc.org

erin.caraher@nyumc.org

kenneth.berger@nyumc.org

joan.reibman@nyumc.org

william.rom@nyumc.org

prezand@fdny.nyc.gov

*Indicates equivalent co-authorship

Conflict of Interest

There are no conflicts of interest.

development or protection from abnormal FEV_1 < lower limit of normal (LLN) known as WTC-LI. We utilized a nested case-cohort control design of previously healthy never smokers who sought subspecialty pulmonary evaluation to explore predictive biomarkers of WTC-LI. We have identified biomarkers of Inflammation, metabolic derangement, protease/antiprotease balance and vascular injury expressed in serum within 6 months of WTC exposure that were predictive of their FEV_1 up to 7 years after their WTC exposure. Predicting future risk of airway injury after particulate exposures can focus monitoring and early treatment on a subset of patients in greatest need of these services.

Keywords

World Trade Center; Lung Injury; Predictive Biomarkers; Obstructive Airway Disease

Occupational Exposure and the Development of Obstructive Airways Disease (OAD)

There is mounting evidence that occupational exposures are a cause of OAD.¹ Occupational exposures are varied but often consist of particulate matter (PM) and other toxins. Epidemiologic evidence links PM exposure to the development of vascular and pulmonary diseases.²⁻⁴ The development of OAD from PM induced inflammation and smoke is poorly understood,⁵ but studies have shown that exposure to high ambient PM significantly decreases forced expiratory volume over 1 second (FEV_1) after 5-7 days.^{6,7} Long-term exposure to air pollutants from motor vehicles and other sources impairs lung function.⁸⁻¹² Upper respiratory symptoms increase by 3% per 10 mcg/m³ of PM exposure.^{6,13}

WTC Particulate Matter Exposure

The destruction of the WTC led to the release of an estimated 10 million tons of material, exposing over 300,000 rescue workers and New York City (NYC) residents and local workers to WTC particulate matter (WTC-PM).¹⁴⁻¹⁶ The concentrations of airborne and respirable WTC-PM ranged from 1-100 mg/m³ immediately after the WTC collapse.¹⁷⁻¹⁹ One month after the event, $PM_{2.5}$ (< 2.5 microns) concentration was 196 mcg/m³, three times the National Ambient Air Quality Standards 24 hour standard.²⁰ The toxicology and physical properties of WTC-PM have been well described.^{18,21} WTC-PM is primarily composed of pulverized concrete, plastics and other hydrocarbons. WTC-PM was found to be highly alkaline; pH 9-11.^{18,22} Exposure to both fine ($PM_{2.5}$) and coarse (PM_{53} , >53 microns) PM has been implicated in the development of lung injury.^{23,24}

Many rescue and recovery workers as well as residents and local workers continued to be exposed to dust for at least three months.²⁵ Induced sputum of NYC firefighters who were exposed to WTC-PM post 9/11 showed increased amounts of PM (1-50µm), neutrophils, and eosinophils even 10 months after the original exposure.²⁶ In a case series of symptomatic local residents and community workers that underwent lung biopsy several years after 2001, emphysematous change, and small airway abnormalities, and rare cases of interstitial fibrosis were seen. Furthermore, opaque and birefringent particles were found

within the macrophages of all cases, and particulate analysis showed these particles to be similar in composition to WTC particulates.²⁷

WTC Associated Pulmonary Function and Radiographic Phenotype

Respiratory compromise has been documented in FDNY rescue workers^{19,28-32}, other exposed workers³³ and lower Manhattan residents.³⁴⁻³⁶ These affected WTC exposed individuals continue to have increased symptoms, medication usage, pulmonary disability and lower quality of life 13 years after exposure.^{19,20,22,24,28-32,37-76} Thus far, the physiologic and radiographic phenotype associated with WTC exposure has been heterogeneous in nature, Table 1. Many exposed individuals have bronchial wall thickening and air trapping on CT. Emphysema, COPD, and OAD occur, but some studies have shown that there is a significant restrictive phenotype seen.

The Utility of Biomarkers of Occupational Lung Function Loss

Identification of biomarkers of disease progression is crucial to guide early intervention as well as treatment. In addition, identification of biomarkers of disease has potential to direct future research into mechanisms producing airflow obstruction. These biomarkers can also identify those at risk who would most benefit from avoidance of further exposure or aggressive management. Measuring biomarkers in serum is a powerful and cost effective approach for risk factor discovery. Immediately after 9/11, the FDNY-Bureau of Health Services (BHS) began implementing protocols for obtaining, processing, storing and retrieving serum from the WTC-exposed firefighters. This cohort of nearly 16,000 Fire Department of New York (FDNY) rescue workers (firefighters, paramedics and emergency medical technicians) form a well-characterized cohort that has been a powerful resource for documenting the impact of WTC exposure on the lung, Figure 1. Serum samples were obtained on a majority of the cohort from September, 2001 to February, 2002, at initial development of airflow obstruction. Taking advantage of this unique cohort, our group has investigated predictive biomarkers of WTC-associated lung injury.⁷⁷⁻⁷⁹ We have identified biomarker subtypes that may be indicators of associated pathways active in the development of WTC associated end-organ dysfunction. This paper is dedicated to reviewing our findings and their physiologic importance.

For biomarker discovery, we chose to focus on FEV₁ as outcome and indicator of disease state. Spirometry had been measured annually in the FDNY cohort three years prior to 9/11/2001, and this cohort continued to receive annual pulmonary function tests (PFTs) as part of the FDNY-WTC-Medical Monitoring and Treatment Program (MMTP). This longitudinal surveillance allowed us to document that in the first year after 9/11, there was a decline in FEV₁ in exposed FDNY rescue workers at a rate twelve times greater than that found pre-9/11.^{29,80} Further evaluation showed that firefighters who had never smoked lost an average of 439 mL of FEV₁ in the first year post-9/11, followed by a mean annualized reduction in FEV₁ of 26 mL per year in the subsequent 6.5 years.^{19,66} In addition, acute airway inflammation, reactive airway dysfunction, and overall decline in FEV₁ have been reported in rescue workers exposed to WTC-PM.^{31,67}

Our study cohort demonstrated a reduced FEV₁ below the lower limits of normal (LLN) was consistent with an obstructive pattern^{67,81} with a low FEV₁/FVC ratio (median 72, IQR 65-77). This suggested that FEV₁<LLN could be used as a surrogate for obstruction in this population. We therefore defined WTC-Lung Injury (WTC-LI) in this population of firefighters by their FEV₁<LLN measured during subspecialty visit after exposure and upon becoming symptomatic. Measurement of FEV₁ is robust and easily measurable. Furthermore, FEV₁ has been the primary endpoint in trials of therapeutic agents and has been used to track health outcomes in numerous lung diseases, including chronic obstructive pulmonary disease (COPD).⁸²

Design of the FDNY-WTC Biomarker Study

At their first FDNY medical monitoring exam (MME) post-9/11, all participants received PFT and serum aliquots were collected and deposited in a biorepository, Figure 1. Symptomatic firefighters were referred to subspecialty pulmonary evaluation between 9/12/2001 and 3/10/2008.⁸³

Nested Case-Cohort Control Study Design

We used a nested case-cohort control strategy to define biomarker expression, Figure 1.⁸⁴⁻⁸⁷ The baseline cohort was derived from 1,720 exposed workers who needed subspecialty pulmonary evaluation and treatment within 6.5 years of 9/11. There was significant inter-individual variation in lung function with some patients recovering and others suffering loss of lung function thereby allowing us to study both outcomes in a similarly exposed cohort.^{46,88} A homogeneous sub-cohort of subjects without prior lung disease or tobacco use was identified after applying inclusion criteria (n=801). The two case subgroups (n=100 for each) were intended to over-sample those *susceptible* and *resistant* to WTC-LI. Those susceptible to WTC-LI had FEV₁<LLN and included patients in the bottom octile of FEV₁% predicted at the time of sub-specialty pulmonary exam. In contrast, the resistant population included those identified in the top octile of FEV₁% predicted at the same time point, and had FEV₁ ≥ LLN. The cohort (n=801) was stratified on tertiles of FEV₁ and BMI, and the cohort control (n=171) was randomly selected. This cohort control has overlapping populations with the susceptible and resistant populations, and ensures sufficient representation of the general FDNY population. All subjects signed informed Institutional Review Board-approved consent at the time of enrollment allowing analysis of their information and samples for research (Montefiore Medical Center; #07-09-320 and New York University; #11-00439). Serum samples were analyzed utilizing Luminex as previously described.^{40,50} Both case definitions and cohort-controls were randomized to batches in a 1:1:2 ratio to avoid batch effect bias and analyzed contemporaneously to avoid variability in time dependent sample decay.^{85,89}

All demographics were obtained from the FDNY-WTC-monitoring database. Degree of exposure was self-reported at the first FDNY-WTC-monitoring and was categorized using the FDNY-WTC Exposure Intensity Index based on Arrival Time: 1. Present on the morning of 9/11/2001 2. Arrived between the afternoon of 9/11/2001 and 9/12/2001.⁶⁷ Those arriving

after day three were excluded from analysis as a result of their low numbers in this sample.^{49,90}

Serum Biomarkers of WTC-LI

Biomarkers of Inflammation

We hypothesized that individuals susceptible to airflow obstruction, induced by environmental irritants, would express different levels of pro-inflammatory cytokines compared to similarly exposed individuals in the cohort-control. We identified inflammatory cytokines and chemokines in the serum of FDNY rescue workers obtained within six months of 9/11 using commercially available multiplex kits, Figure 1. We correlated inflammatory biomarkers at monitoring entry with FEV₁ at sub-specialty pulmonary exam. Cases of those susceptible to WTC-LI with FEV₁<LLN were compared to controls with FEV₁ ≥ LLN. From monitoring entry to sub-specialty pulmonary exam years later, FEV₁ declined 12% in cases and increased 3% in controls. Elevated Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and Macrophage Derived Chemokine (MDC) increased the risk for subsequent FEV₁<LLN by 2.5 fold and 3.0 fold in a logistic regression model adjusted for exposure, BMI, age on 9/11, and neutrophil, Figure 2A. Roles for GM-CSF and MDC in airway injury are biologically plausible in that human bronchial epithelial cells produce GM-CSF in response to PM and MDC is elevated in bronchoalveolar lavage of asthmatics. The model had sensitivity of 38% and a specificity of 88%. The low sensitivity suggested other biomarkers not yet identified were significant risk factors for accelerated decline of lung function after irritant exposure at the WTC site.

Metabolic Biomarkers as Predictors of WTC Lung Function Loss

Metabolic syndrome (MetSyn) is a principal contributor to systemic inflammation associated end organ damage.⁹¹ This interaction is best understood in vascular diseases, but previous cross sectional studies have suggested associations of impaired lung function with MetSyn.⁹²⁻⁹⁶

Utilizing our case-cohort control study design, we diagnosed MetSyn using World Health Organization (WHO)-modified National Heart Lung and Blood Institute/American Heart Association criteria. Subjects had to meet three of the following five criteria: *i.* Elevated triglycerides ≥ 150 mg/dL (1.7mmol/L). *ii.* Reduced High Density Lipoprotein (HDL) <40 mg/dL in men *iii.* Elevated systolic blood pressure (BP) ≥ 130 mm Hg or diastolic BP ≥ 85 mm Hg *iv.* Elevated fasting glucose ≥ 100 mg/dL.^{97,98} *v.* Body Mass Index (BMI) ≥30 was substituted for increased waist circumference as per WHO Criteria.⁹⁹ Concurrent fasting blood levels of HDL, Glucose, and triglycerides were assayed when the subjects' first post-9/11 serum samples were collected and banked at monitoring entry.

We found that cases of WTC-LI had significantly higher glucose and heart rate at monitoring entry than controls. However, cases did not have significantly different triglycerides, systolic blood pressure, or HDL. There was a trend of a higher percentage of individuals with MetSyn in cases compared to controls (27% vs 16%, p=0.07). Cases had a larger proportion of individuals with higher glucose (28% vs 16%, p=0.03) and lower HDL (32% vs 20%, p=0.05). The differences in lipid profiles between cases and controls were

accentuated when individuals had combined abnormalities in triglycerides and HDL (dyslipidemia, defined as triglycerides ≥ 150 mg/dL and HDL < 40 mg/dL) (28% vs 14%, $p=0.006$). In addition, we defined a heart rate above the median of 66 beats per minute (bpm) as elevated for the entire nonsmoking cohort. Cases compared to controls had a larger proportion with elevated heart rate (65% vs 48% $p=0.02$). We then defined cut points for metabolic analytes using the top quartile for leptin and amylin.

We assessed if any of the biomarkers with significantly different prevalence altered the odds ratio (OR) of being a case using logistic models adjusted for BMI, age on 9/11, race and WTC arrival time. When biomarkers and clinical parameters were included in the final model, dyslipidemia, elevated heart rate and elevated leptin significantly increased the odds of being a case: Dyslipidemia, OR=3.03, heart rate ≥ 66 bpm, OR=2.20 and leptin $\geq 10,300$ pg/mL OR=3.00, Figure 2A. Elevated amylin was strongly protective, decreasing the odds of being a case by 84%, Figure 2A. We assessed the ability of the final logistic regression model to predict case status using receiver operating characteristic (ROC) analysis. The final model had an area under the curve (AUC) of 0.774 after adjusting for previously mentioned covariates.

Biologically active lipid metabolites are biologically plausible pathways of disease and can be attenuated pharmacologically. As a logical extension of our earlier work we therefore turned our attention to Lysophosphatidic acid (LPA), an LDL derivative and Apolipoprotein (Apo)A1, a component of HDL. LPA activates pathways involved in vascular injury.¹⁰⁰⁻¹⁰³ Vascular injury occurs early in smoking related COPD with pulmonary perfusion abnormalities and reduced blood return to the heart observed prior to development of abnormal FEV₁.^{104,105} Similar pathophysiology likely occurs in irritant induced COPD. Pulmonary arteriopathy was present in 58% of lung biopsies from non-FDNY WTC-PM exposed individuals and in 74% with constrictive bronchiolitis after inhalational exposures suffered during military service in Iraq and Afghanistan.^{27,106}

To assess the relationship between LPA and ApoA1 with the outcome of being a susceptible case, we used a multivariable logistic model (adjusted for BMI, exposure intensity, pre-9/11 FEV₁% predicted, age on 9/11, race, WTC exposure, dyslipidemia, platelet and neutrophil count). In the adjusted model, a 10 μ M increase of LPA was associated with a 14% increase in the odds of having WTC-LI while an increase of 1 mg/mL of ApoA1 increased the odds of developing WTC-LI by 29%. These findings further demonstrate the biological relevance of lipids and their metabolites in the progression of OAD after WTC exposures.

Vascular Biomarkers of WTC-LI

Recent studies associate systemic vascular involvement with lung disease.^{107,108} Prospective studies have demonstrated an association between systemic inflammation, impaired lung function, and central arterial stiffness that occurs prior to the development of cardiovascular disease (CVD).¹⁰⁹⁻¹¹¹ Similarly, perfusion abnormalities and reduced pulmonary blood flow occur prior to development of abnormal FEV₁ in smokers at risk for COPD. Lung biopsies from WTC-PM exposed individuals showed pulmonary arteriopathy and constrictive bronchiolitis secondary to inhalational exposures, and hinted at the potential use of vascular biomarkers associated with WTC-LI.^{27,106}

Vascular biomarkers were investigated in subjects that went on to develop WTC-LI and in those that did not. Individuals with elevated Apolipoprotein (Apo)AII and C-reactive protein (CRP) levels within six months of 9/11 had significantly increased risk of developing decreased lung function over the subsequent six years while elevated Macrophage Inflammatory Protein (MIP-4) reduced the risk of susceptibility to decreased lung function, Figure 2A. Alternately, firefighters with elevated soluble Vascular Cell Adhesion Molecule (sVCAM) and low myeloperoxidase (MPO) levels within six months of 9/11/2001 predicted recovery of lung function, and showed return of FEV₁ to pre-9/11 values after an acute decline post-9/11, Figure 2B.

The biologic plausibility of our findings is significantly supported by the literature. CRP is a known marker of acute systemic inflammation and CVD that has been shown to have an inverse relationship with FEV₁.¹¹²⁻¹¹⁴ CRP levels were elevated in individuals with COPD independent of any CVD risks.¹¹⁵ Pulmonary hypertension, a disease of the pulmonary vasculature, is associated with CVD biomarkers such as apolipoprotein.¹¹⁶ This parallels our prior observation that dyslipidemia predicts poor outcome after WTC dust exposure.

Macrophage inflammatory protein-4 (MIP-4) was inversely associated with odds of developing WTC-LI. This finding contrasts with that of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort, in which elevated MIP-4 was associated with concurrent COPD, increased risk of cardiovascular hospitalization and mortality.¹¹⁷ The difference in the association of MIP-4 may be due to the timing of the biomarker studies; our cohort had blood biomarkers prior to disease presentation, whereas the ECLIPSE study focused on end-stage disease. MIP-4 (CCL18, PARC) is an early promoter of regulatory T-cell differentiation and may generate an anti-inflammatory counter-regulatory response that leads to protection of lung injury in our group.^{118,119} Finally, low levels of MPO demonstrate less neutrophil activation, an important mediator of PM-induced pulmonary and cardiovascular injury. In our group, it was associated with resistance to the damaging effects of WTC-PM exposure.^{120,121} Our data and other recent reports emphasize the need to better understand the mechanisms by which inhaled irritants damage pulmonary vessels.

In addition to serum biomarkers of vascular involvement, our group and others have investigated quantifiable vasculometric changes associated with OAD. An increased ratio of the pulmonary artery to aorta (PA/A) diameter measured by computed tomography (CT) has been associated with pulmonary hypertension and poor outcomes in various disease states. The elevated PA/A ratio implies relative pulmonary vascular enlargement and has been associated with past and future exacerbations in patients with moderate-to-severe COPD.¹²² PA/A has been associated with a decreased FEV₁ in the same population. Furthermore, in subjects with CVD a PA/A ratio >1 has been associated with increased mortality.¹²³ PA/A from chest CT scans obtained for clinical indications in our case cohort control population were calculated. Using the Youden index, a PA/A value of 0.92 was selected as the cutoff for best predicting the development of WTC-LI in a logistic regression analysis. After adjusting for age at CT, pre-9/11 FEV₁, BMI at sub-specialty pulmonary evaluation and exposure, the odds of having World Trade Center Lung Injury in patients with a value of PA/A = 0.92 was 4.02, Figure 2.

In the ECLIPSE/COPD Gene cohort, PA/A >1 was associated with disease severity and subjects had more advanced disease than in the FDNY-WTC cohort.¹²² Although our cohort's mean PA and A were similar to those measured in ECLIPSE/COPD Gene cohort, 81% of our cohort did not meet GOLD COPD criteria. Therefore, it was expected that the PA/A would be less than previously reported ratios of 1.¹²² When comparing our cohort to the Framingham Heart Study, our case mean PA/A and PA values are similar to their 90th% upper limit of normal.¹²⁴ Our study suggests that the PA/A ratio 0.92 may represent a marker of early vascular injury in particulate matter related lung disease and is in line with these recent publications.

Protease/ Antiprotease Balance as Biomarkers of WTC-LI

The balance of protease/anti-protease activity is the crux of many diseases including cigarette-induced chronic lung disease and other causes of accelerated lung function decline.¹²⁵⁻¹²⁸ The serine antiprotease α -1 Antitrypsin (AAT) predicts accelerated FEV₁ decline in WTC exposed firefighters and is a well-studied biomarker of smoking associated lung disease.¹²⁹ To determine the impact of AAT levels on FEV₁ decline after WTC exposure, AAT levels and genotype were assayed in 90 randomly selected subjects. The rate of FEV₁ loss increased with increasing AAT deficiency defined either by genotype or serum concentration. Moderately (MS or SZ genotype) deficient rescue workers' FEV₁ declined 110cm³/year more than normal, while mildly (MS or SS genotype) deficient rescue workers lost 32cm³/year more than normal. Rescue workers with AAT serum levels below 20 μ mol/l lost 49 cm³/year of FEV₁ compared to workers with AAT levels greater than or equal to 20 μ mol/l. There was no impact of AAT levels or genotype on spirometric decline rates prior to 09/11/2001 suggesting an interaction between low AAT and WTC exposure.¹³⁰ In data previously unreported, utilizing our case-cohort control study we found that AAT <85 mg/dL increased the risk of developing WTC-LI, Figure 2A.¹³¹⁻¹³³

Matrix metalloproteinases (MMPs) can catabolize and degrade the extracellular matrix.¹³⁴ Many are known intermediates of each other, and their levels are affected by environmental factors such as hypoxia, inflammation and oxidative stress. Several MMPs can be either directly inhibited by or form complexes with TIMPs. MMP/TIMP balance is another well-defined mediator of COPD.¹³⁴

Genetic association studies with MMPs demonstrate a strong association with the development of lung disease.¹²⁵ MMP-1 is induced in smokers with COPD and its overexpression in mice causes emphysema.^{135,136} The destructive effects of MMPs are inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs). There is little data on the role of MMPs and TIMPs in the resistance to the damaging effect of dust exposure.¹³⁷⁻¹⁴⁰ One carefully done pathologic study demonstrated increased MMP-2 and TIMP-1 mRNA expression in surgically removed lung and predicted improved FEV₁ in COPD patients.¹⁴¹ As serum MMP and TIMP expression is related to the development of COPD, the link between serum MMP/TIMP balance and lung function in the WTC exposed cohort became the focus of our next set of investigations.¹⁴²

In investigating susceptible cases, elevated serum levels of MMP-3 and MMP-12 reduce the risk of developing WTC-LI. Increased time between 9/11 and blood draw is associated with a diminished protective effect. Specifically, early elevated expression of MMP-3 and MMP-12 in serum within 200 days after WTC exposure predicts protected lung function over the subsequent seven years (2001-2008). We found that MMP-3 and MMP-12 ranges of the cohort were comparable to other published patient populations, including healthy controls and patient cohorts with emphysema or rheumatoid arthritis.^{143,144} MMP-3 was found to be more protective than MMP-12, Figure 2A. Both biomarker models displayed robust predictive ability by logistic regression with AUC>0.8.

Compared to susceptible cases, the resistant cases had greater than average reduction in FEV₁ immediately after exposure, but returned to pre-exposure FEV₁ over the next 6.5 years. Because serum was drawn well before the pulmonary function test that demonstrated recovery, the biomarker information reflected evolving injury. All subjects in this nested case control investigation had heavy WTC dust exposure and arrived at the collapse site within 2 days of 9/11/2001. MMP-2 and TIMP-1 expression above the 75th percentile are protective biomarkers, significantly increasing the odds of resistance between 4.2 and 5.4 fold. Alternately, elevated MMP-1 is a risk factor, reducing the odds of resistance by 73%, Figure 2B. The biomarker model using serum MMP-1, MMP-2 and TIMP-1 concentration predicted resistance with a sensitivity of 74%, a specificity of 86% and a receiver operator characteristic of 0.90.⁴⁰

Innate and Humoral Mediators

The ratio of FEV₁/Forced Vital Capacity (FVC) is another well-validated spirometric measure of airflow obstruction. Genome wide association studies (GWAS) observed that a set of genetic variants of chitinases are associated with only FEV₁. Polymorphisms at other loci can predict FEV₁/FVC and both FEV₁ and FEV₁/FVC.^{145,146} Biomarkers predicting abnormal FEV₁/FVC may therefore be distinct from those predicting abnormal FEV₁. Hence, we investigated if biomarkers expressed within 6 months of 9/11/2001 predicted future abnormal FEV₁/FVC in this WTC exposed cohort. In this investigation, we evaluated innate and humoral mediators. We found that increased serum chitotriosidase (CHIT) reduces the odds of developing obstruction after WTC-particulate matter exposure and is associated with recovery of lung function. Alternately, elevated Immunoglobulin E (IgE) was a risk factor for airflow obstruction and progressive lung function decline.

CHIT belongs to the glycosyl hydrolase 18 gene family that binds and cleaves chitin. CHIT is part of the innate host defense against bacterial and fungal infections since chitin is a major structural component in bacteria, fungi, insects and crustaceans.¹⁴⁷⁻¹⁵¹ CHIT is produced in mature monocyte-derived macrophages, lung macrophages and other specific subsets of tissue macrophages.¹⁵²⁻¹⁵⁵ Elevated chitotriosidase expression is associated with smoking induced and fibrotic lung disease.^{156,157} However, its biological function has not been clearly defined.

IgE-mediated humoral immunity is another important immune response mechanism in the respiratory tract.¹⁵⁸ Elevated IgE is a key immune mediator in asthma. Children and adults with asthma have higher IgE than normal controls and anti-IgE antibody is an effective

asthma modulator.¹⁵⁹⁻¹⁶² Elevated serum IgE is strongly associated with low FEV₁/FVC in patients with chronic obstructive lung disease.¹⁶³

SUMMARY

Identification of serum biomarkers that predict lung disease can direct future research into mechanisms producing airflow obstruction, fuel future work about their downstream effects, aid in the development of diagnostic markers and potential therapeutic targets in clinical trials. Our study cohort, with clinical information before and after a significant environmental exposure, serves as a unique opportunity to identify biomarkers associated and predictive of lung and vascular disease. Although many studies have focused on occupational biomarker identification, our study cohort has lung function assessment prior to exposure and development of disease. This is ideal for the study of predictive biomarkers, and has allowed us to establish leadership in pathophysiologic investigation of WTC-LI.⁷⁷⁻⁷⁹

We have developed a high-dimensional dataset that includes at least 130 serum and radiographic biomarkers in a cohort of firefighters with intense exposure to World Trade Center dust. We have identified multiple biomarkers of biologically plausible pathways that are active in the development of WTC-associated end-organ dysfunction. It was necessary to develop a parsimonious biomarker model that would generate reproducible and generalizable findings. To optimize identification of candidate biomarkers from a relatively small sample size we utilized a case cohort control for much of our work. Furthermore, the small sample size in a high-dimensional biomarker dataset could obscure potential pathways of interest, we studied biomarkers in separate but often related pathways to further optimize signal to noise. Future work will include repeated serum sampling to add a longitudinal component to the FDNY-NYU biorepository. This will expand our understanding of biomarker evolution and will be a resource for investigating other long latency WTC related diseases.

Development of OAD following particulate matter exposure is a major health concern worldwide. First responders and the military may be specifically more affected by the high amounts of particulate exposure during disasters and conflict. Identifying predictive biomarkers of FEV₁ loss allows for early identification of at risk individuals allowing for early screening, necessary treatment and risk avoidance. While unique in many ways, the exposures on 9/11/2001 have allowed us to make observations related to lung disease progression that may translate to other occupationally and environmentally exposed populations. The processes initiated by WTC exposure impacted multiple distinct injury and repair pathways. Our prior studies and this review emphasize the utility of serum stored in the aftermath of a disaster. The insight into protein expression in OAD gained from the analysis of this serum has the potential to guide future mechanistic and therapeutic studies designed to blunt the impact of the worldwide COPD epidemic.

Acknowledgments

This work was supported by NIH-NHLBI K23HL084191(AN), NIAID (MDW) K24A1080298, NIH-R01HL057879 (MDW), and NIOSH (U10-OH008243, U10-OH008242) and UL1RR029893 (DJP). This work was also partially funded by the NYU-HHC

Clinical and Translational Science Institute is supported in part by grant UL1TR000038 from the National Center for Advancing Translational Sciences of the National Institutes of Health.

The funding agencies did not participate in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

ABBREVIATIONS

AT	Air Trapping
AAT	Alpha-1 Antitrypsin
Apo	Apolipoprotein
AUC	Area under the curve
BHS	Bureau of Health Services
BMI	Body Mass Index
BP	Blood Pressure
BPM	Beats per Minute
BWT	Bronchial Wall Thickening
CHIT	Chitotriosidase
COPD	chronic obstructive pulmonary disease
CVD	Cardiovascular Disease
DL_{CO}	Diffusion Capacity of the Lung for Carbon Monoxide
Dyslipidemia	HDL<40 mg/dL and Triglycerides 150 mg/dL
ECLIPSE	Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints
FDNY	Fire Department of New York
FEV₁	Forced Expiratory Volume in one second
FVC	Forced Vital Capacity
GM-CSF	Granulocyte Macrophage-Colony Stimulating Factor
GOLD	Global Initiative for Chronic Obstructive Lung disease
GWAS	Genome wide association studies
HDL	High Density Lipoprotein
IgE	Immunoglobulin E
IL-6	Interleukin-6

LLN	Lower Limit of Normal as defined by NHANES III
LPA	Lysophosphatidic acid
MDC	Macrophage Derived Chemokine
MetSyn	Metabolic Syndrome
MME	Medical Monitoring Exam
MIP-4	Macrophage Inflammatory Protein
MMP	Matrix metalloproteinases
MMTP	Medical Monitoring Treatment Program
MPO	Myeloperoxidase
NAAQS	National Ambient Air Quality Standards
NHANES	National
NYC	New York City
NYPD	New York Police Department
NYU	New York University
OAD	Obstructive Airways Disease
OR	Odds Ratio
PA/A	Pulmonary Artery/Aorta
PFT	Pulmonary Function Test
PM	Particulate Matter
sRAGE	soluble Receptor for Advanced Glycation End Products
ROC	Receiver Operator Characteristics
sVCAM	soluble Vascular Cell Adhesion Molecule
TIMP	tissue inhibitors of matrix metalloproteinases
TLC	Total Lung Capacity
TNF-α	Tumor Necrosis Factor-alpha
WHO	World Health Organization
WTC	World Trade Center
WTC-LI	World Trade Center-Lung Injury
WTC-PM	World Trade Center-Particulate Matter

References

1. Blanc PD, Eisner MD, Earnest G, et al. Further exploration of the links between occupational exposure and chronic obstructive pulmonary disease. *J Occup Environ Med.* 2009; 51:804–10. [PubMed: 19528835]

2. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. *N Engl J Med*. 2000; 343:1742–9. [PubMed: 11114312]
3. Thurston GD, Ito K, Hayes CG, Bates DV, Lippmann M. Respiratory hospital admissions and summertime haze air pollution in Toronto, Ontario: consideration of the role of acid aerosols. *Environ Res*. 1994; 65:271–90. [PubMed: 8187742]
4. Dockery DW, Pope CA 3rd, Xu X, et al. An association between air pollution and mortality in six U.S. cities. *N Engl J Med*. 1993; 329:1753–9. [PubMed: 8179653]
5. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. *PLoS Med*. 2010; 7:e1000220. [PubMed: 20305715]
6. Hoek G, Brunekreef B. Acute effects of a winter air pollution episode on pulmonary function and respiratory symptoms of children. *Arch Environ Health*. 1993; 48:328–35. [PubMed: 8215597]
7. Brunekreef B, Kinney PL, Ware JH, et al. Sensitive subgroups and normal variation in pulmonary function response to air pollution episodes. *Environ Health Perspect*. 1991; 90:189–93. [PubMed: 2050060]
8. Ackermann-Lieblich U, Leuenberger P, Schwartz J, et al. Lung function and long term exposure to air pollutants in Switzerland. Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. *Am J Respir Crit Care Med*. 1997; 155:122–9. [PubMed: 9001300]
9. Brunekreef B, Holgate ST. Air pollution and health. *Lancet*. 2002; 360:1233–42. [PubMed: 12401268]
10. Franco, Suglia S.; Gryparis, A.; Schwartz, J.; Wright, RJ. Association between traffic-related black carbon exposure and lung function among urban women. *Environ Health Perspect*. 2008; 116:1333–7. [PubMed: 18941574]
11. Gotschi T, Heinrich J, Sunyer J, Kunzli N. Long-term effects of ambient air pollution on lung function: a review. *Epidemiology*. 2008; 19:690–701. [PubMed: 18703932]
12. Kan H, Heiss G, Rose KM, Whitsel E, Lurmann F, London SJ. Traffic exposure and lung function in adults: the Atherosclerosis Risk in Communities study. *Thorax*. 2007; 62:873–9. [PubMed: 17442705]
13. Ostro BD, Lipsett MJ, Mann JK, Krupnick A, Harrington W. Air pollution and respiratory morbidity among adults in southern California. *Am J Epidemiol*. 1993; 137:691–700. [PubMed: 8484360]
14. Landrigan PJ. Health consequences of the 11 September 2001 attacks. *Environ Health Perspect*. 2001; 109:A514–5. [PubMed: 11713006]
15. Aldrich TK, Gustave J, Hall CB, et al. Lung function in rescue workers at the World Trade Center after 7 years. *N Engl J Med*. 362:1263–72. [PubMed: 20375403]
16. Claudio L. Environmental aftermath. *Environ Health Perspect*. 2001; 109:A528–36. [PubMed: 11713010]
17. Chen LC, Thurston G. World Trade Center cough. *Lancet*. 2002; 360(Suppl):s37–8. [PubMed: 12504497]
18. McGee JK, Chen LC, Cohen MD, et al. Chemical analysis of World Trade Center fine particulate matter for use in toxicologic assessment. *Environ Health Perspect*. 2003; 111:972–80. [PubMed: 12782501]
19. Prezant DJ, Weiden M, Banauch GI, et al. Cough and bronchial responsiveness in firefighters at the World Trade Center site. *N Engl J Med*. 2002; 347:806–15. [PubMed: 12226151]
20. Rom WN, Reibman J, Rogers L, et al. Emerging exposures and respiratory health: World Trade Center dust. *Proc Am Thorac Soc*. 2010; 7:142–5. [PubMed: 20427588]
21. Lioy PJ, Weisel CP, Millette JR, et al. Characterization of the dust/smoke aerosol that settled east of the World Trade Center (WTC) in lower Manhattan after the collapse of the WTC 11 September 2001. *Environ Health Perspect*. 2002; 110:703–14. [PubMed: 12117648]
22. Lioy PJ, Pellizzari E, Prezant D. The World Trade Center aftermath and its effects on health: understanding and learning through human-exposure science. *Environ Sci Technol*. 2006; 40:6876–85. [PubMed: 17153990]
23. Gavett, SH.; United States. Environmental Protection Agency. Office of Research and Development. National Health and Environmental Effects Research Laboratory (U.S.). Toxicological effects of fine particulate matter derived from the destruction of the World Trade

- Center. National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency; Research Triangle Park, N.C.: 2002.
24. Rom WN, Weiden M, Garcia R, et al. Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. *Am J Respir Crit Care Med*. 2002; 166:797–800. [PubMed: 12231487]
 25. Landrigan PJ, Liroy PJ, Thurston G, et al. Health and environmental consequences of the world trade center disaster. *Environ Health Perspect*. 2004; 112:731–9. [PubMed: 15121517]
 26. Fireman EM, Lerman Y, Ganor E, et al. Induced sputum assessment in New York City firefighters exposed to World Trade Center dust. *Environ Health Perspect*. 2004; 112:1564–9. [PubMed: 15531443]
 27. Caplan-Shaw CE, Yee H, Rogers L, et al. Lung pathologic findings in a local residential and working community exposed to World Trade Center dust, gas, and fumes. *J Occup Environ Med*. 2011; 53:981–91. [PubMed: 21860325]
 28. Banauch GI, Dhala A, Alleyne D, et al. Bronchial hyperreactivity and other inhalation lung injuries in rescue/recovery workers after the World Trade Center collapse. *Crit Care Med*. 2005; 33:S102–6. [PubMed: 15640671]
 29. Banauch GI, Hall C, Weiden M, et al. Pulmonary function after exposure to the World Trade Center collapse in the New York City Fire Department. *Am J Respir Crit Care Med*. 2006; 174:312–9. [PubMed: 16645172]
 30. Feldman DM, Baron SL, Bernard BP, et al. Symptoms, respirator use, and pulmonary function changes among New York City firefighters responding to the World Trade Center disaster. *Chest*. 2004; 125:1256–64. [PubMed: 15078732]
 31. Banauch GI, Alleyne D, Sanchez R, et al. Persistent hyperreactivity and reactive airway dysfunction in firefighters at the World Trade Center. *Am J Respir Crit Care Med*. 2003; 168:54–62. [PubMed: 12615613]
 32. Banauch GI, Dhala A, Prezant DJ. Pulmonary disease in rescue workers at the World Trade Center site. *Curr Opin Pulm Med*. 2005; 11:160–8. [PubMed: 15699790]
 33. Herbert R, Moline J, Skloot G, et al. The World Trade Center disaster and the health of workers: five-year assessment of a unique medical screening program. *Environ Health Perspect*. 2006; 114:1853–8. [PubMed: 17185275]
 34. Reibman J, Lin S, Hwang SA, et al. The World Trade Center residents' respiratory health study: new-onset respiratory symptoms and pulmonary function. *Environ Health Perspect*. 2005; 113:406–11. [PubMed: 15811830]
 35. From the Centers for Disease Control and Prevention. Self-reported increase in asthma severity after the September 11 attacks on the World Trade Center--Manhattan, New York, 2001. *Jama*. 2002; 288:1466–7. [PubMed: 12353503]
 36. Self-reported increase in asthma severity after the September 11 attacks on the World Trade Center--Manhattan, New York, 2001. *MMWR Morb Mortal Wkly Rep*. 2002; 51:781–4. [PubMed: 12227438]
 37. Glaser MS, Webber MP, Zeig-Owens R, et al. Estimating the time interval between exposure to the world trade center disaster and incident diagnoses of obstructive airway disease. *Am J Epidemiol*. 2014; 180:272–9. [PubMed: 24980522]
 38. Niles JK, Webber MP, Liu X, et al. The upper respiratory pyramid: Early factors and later treatment utilization in World Trade Center exposed firefighters. *Am J Ind Med*. 2014; 57:857–65. [PubMed: 24898816]
 39. Tsukiji J, Cho SJ, Echevarria GC, et al. Lysophosphatidic acid and apolipoprotein A1 predict increased risk of developing World Trade Center-lung injury: a nested case-control study. *Biomarkers*. 2014; 19:159–65. [PubMed: 24548082]
 40. Nolan A, Kwon S, Cho SJ, et al. MMP-2 and TIMP-1 predict healing of WTC-lung injury in New York City firefighters. *Respir Res*. 2014; 15:5. [PubMed: 24447332]
 41. Cho SJ, Echevarria GC, Kwon S, et al. One airway: Biomarkers of protection from upper and lower airway injury after World Trade Center exposure. *Respir Med*. 2014; 108:162–70. [PubMed: 24290899]

42. Kwon S, Weiden MD, Echevarria GC, et al. Early Elevation of Serum MMP-3 and MMP-12 Predicts Protection from World Trade Center-Lung Injury in New York City Firefighters: A Nested Case-Control Study. *PLoS One*. 2013; 8:e76099. [PubMed: 24146820]
43. Niles JK, Webber MP, Cohen HW, et al. The respiratory pyramid: From symptoms to disease in World Trade Center exposed firefighters. *Am J Ind Med*. 2013; 56:870–80. [PubMed: 23788055]
44. Cho SJ, Nolan A, Echevarria GC, et al. Chitotriosidase is a biomarker for the resistance to World Trade Center lung injury in New York City firefighters. *J Clin Immunol*. 2013; 33:1134–42. [PubMed: 23744081]
45. Weakley J, Webber MP, Ye F, et al. Agreement between obstructive airways disease diagnoses from self-report questionnaires and medical records. *Prev Med*. 2013; 57:38–42. [PubMed: 23597657]
46. Weiden MD, Naveed B, Kwon S, et al. Cardiovascular biomarkers predict susceptibility to lung injury in World Trade Center dust-exposed firefighters. *Eur Respir J*. 2013; 41:1023–30. [PubMed: 22903969]
47. Weiden MD, Naveed B, Kwon S, et al. Comparison of WTC dust size on macrophage inflammatory cytokine release in vivo and in vitro. *PLoS One*. 2012; 7:e40016. [PubMed: 22815721]
48. Soo J, Webber MP, Hall CB, et al. Pulmonary function predicting confirmed recovery from lower-respiratory symptoms in World Trade Center-exposed firefighters, 2001 to 2010. *Chest*. 2012; 142:1244–50. [PubMed: 22576633]
49. Naveed B, Weiden MD, Kwon S, et al. Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study. *Am J Respir Crit Care Med*. 2012; 185:392–9. [PubMed: 22095549]
50. Nolan A, Naveed B, Comfort AL, et al. Inflammatory biomarkers predict airflow obstruction after exposure to World Trade Center dust. *Chest*. 2012; 142:412–8. [PubMed: 21998260]
51. Webber MP, Glaser MS, Weakley J, et al. Physician-diagnosed respiratory conditions and mental health symptoms 7–9 years following the World Trade Center disaster. *Am J Ind Med*. 2011; 54:661–71. [PubMed: 21966080]
52. Weakley J, Webber MP, Gustave J, et al. Trends in respiratory diagnoses and symptoms of firefighters exposed to the World Trade Center disaster: 2005–2010. *Prev Med*. 2011; 53:364–9. [PubMed: 21930151]
53. Soo J, Webber MP, Gustave J, et al. Trends in probable PTSD in firefighters exposed to the World Trade Center disaster, 2001–2010. *Disaster Med Public Health Prep*. 2011; 5(Suppl 2):S197–203. [PubMed: 21900417]
54. Zeig-Owens R, Webber MP, Hall CB, et al. Early assessment of cancer outcomes in New York City firefighters after the 9/11 attacks: an observational cohort study. *Lancet*. 2011; 378:898–905. [PubMed: 21890054]
55. Guidotti TL, Prezant D, de la Hoz RE, Miller A. The evolving spectrum of pulmonary disease in responders to the World Trade Center tragedy. *Am J Ind Med*. 2011; 54:649–60. [PubMed: 23236631]
56. Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone JE. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. *J Occup Environ Med*. 2011; 53:966–74. [PubMed: 21860326]
57. Niles JK, Webber MP, Gustave J, et al. The impact of the World Trade Center attack on FDNY firefighter retirement, disabilities, and pension benefits. *Am J Ind Med*. 2011; 54:672–80. [PubMed: 21557282]
58. Niles JK, Webber MP, Gustave J, et al. Comorbid trends in World Trade Center cough syndrome and probable posttraumatic stress disorder in firefighters. *Chest*. 2011; 140:1146–54. [PubMed: 21546435]
59. Munjal KG, Silverman RA, Freese J, et al. Utilization of emergency medical services in a large urban area: description of call types and temporal trends. *Prehosp Emerg Care*. 2011; 15:371–80. [PubMed: 21521036]

60. Chiu S, Niles JK, Webber MP, et al. Evaluating risk factors and possible mediation effects in posttraumatic depression and posttraumatic stress disorder comorbidity. *Public Health Rep.* 2011; 126:201–9. [PubMed: 21387950]
61. Berninger A, Webber MP, Niles JK, et al. Longitudinal study of probable post-traumatic stress disorder in firefighters exposed to the World Trade Center disaster. *Am J Ind Med.* 2010; 53:1177–85. [PubMed: 20862700]
62. Berninger A, Webber MP, Weakley J, et al. Quality of life in relation to upper and lower respiratory conditions among retired 9/11-exposed firefighters with pulmonary disability. *Qual Life Res.* 2010; 19:1467–76. [PubMed: 20680691]
63. Banauch GI, Brantly M, Izbicki G, et al. Accelerated spirometric decline in New York City firefighters with alpha(1)-antitrypsin deficiency. *Chest.* 2010; 138:1116–24. [PubMed: 20634282]
64. Berninger A, Webber MP, Cohen HW, et al. Trends of elevated PTSD risk in firefighters exposed to the World Trade Center disaster: 2001-2005. *Public Health Rep.* 2010; 125:556–66. [PubMed: 20597456]
65. Webber MP, Lee R, Soo J, et al. Prevalence and incidence of high risk for obstructive sleep apnea in World Trade Center-exposed rescue/recovery workers. *Sleep Breath.* 2011; 15:283–94. [PubMed: 20593281]
66. Aldrich TK, Gustave J, Hall CB, et al. Lung function in rescue workers at the World Trade Center after 7 years. *N Engl J Med.* 2010; 362:1263–72. [PubMed: 20375403]
67. Weiden MD, Ferrier N, Nolan A, et al. Obstructive airways disease with air trapping among firefighters exposed to World Trade Center dust. *Chest.* 2010; 137:566–74. [PubMed: 19820077]
68. Webber MP, Gustave J, Lee R, et al. Trends in respiratory symptoms of firefighters exposed to the world trade center disaster: 2001-2005. *Environ Health Perspect.* 2009; 117:975–80. [PubMed: 19590693]
69. Chiu S, Webber MP, Zeig-Owens R, et al. Validation of the Center for Epidemiologic Studies Depression Scale in screening for major depressive disorder among retired firefighters exposed to the World Trade Center disaster. *J Affect Disord.* 2010; 121:212–9. [PubMed: 19539999]
70. Prezant DJ, Levin S, Kelly KJ, Aldrich TK. Upper and lower respiratory diseases after occupational and environmental disasters. *Mt Sinai J Med.* 2008; 75:89–100. [PubMed: 18500710]
71. Banauch GI, Izbicki G, Christodoulou V, et al. Trial of prophylactic inhaled steroids to prevent or reduce pulmonary function decline, pulmonary symptoms, and airway hyperreactivity in firefighters at the world trade center site. *Disaster Med Public Health Prep.* 2008; 2:33–9. [PubMed: 18388656]
72. Prezant DJ. World Trade Center Cough Syndrome and its treatment. *Lung.* 2008; 186(Suppl 1):S94–102. [PubMed: 18027025]
73. Izbicki G, Chavko R, Banauch GI, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. *Chest.* 2007; 131:1414–23. [PubMed: 17400664]
74. Truncale T, Brooks S, Prezant DJ, Banauch GI, Nemery B. World Trade Center dust and airway reactivity. *Am J Respir Crit Care Med.* 2004; 169:883–4. author reply 4-5. [PubMed: 15044224]
75. Edelman P, Osterloh J, Pirkle J, et al. Biomonitoring of chemical exposure among New York City firefighters responding to the World Trade Center fire and collapse. *Environ Health Perspect.* 2003; 111:1906–11. [PubMed: 14644665]
76. Kelly KJ, Connelly E, Reinhold GA, Byrne M, Prezant DJ. Assessment of health effects in New York City firefighters after exposure to polychlorinated biphenyls (PCBs) and polychlorinated dibenzofurans (PCDFs): the Staten Island Transformer Fire Health Surveillance Project. *Arch Environ Health.* 2002; 57:282–93. [PubMed: 12530594]
77. Holguin F. The metabolic syndrome as a risk factor for lung function decline. *Am J Respir Crit Care Med.* 2012; 185:352–3. [PubMed: 22336675]
78. Balmes JR. Can we predict who will develop chronic sequelae of acute inhalational injury? *Chest.* 2012; 142:278–9. [PubMed: 22871748]
79. Antao VC. The World Trade Center disaster: a tragic source of medical advancement. *Eur Respir J.* 2013; 41:999–1001. [PubMed: 23633605]

80. Naveed B, Weiden MD, Kwon S, et al. Metabolic Syndrome Biomarkers Predict Lung Function Impairment: A Nested Case-Control Study. *Am J Respir Crit Care Med*. 2011
81. Berger KI, Reibman J, Oppenheimer BW, Vlahos I, Harrison D, Goldring RM. Lessons from the World Trade Center disaster: airway disease presenting as restrictive dysfunction. *Chest*. 2013; 144:249–57. [PubMed: 23392588]
82. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2009; 6:543–5. [PubMed: 19741266]
83. Weiden MD, Ferrier N, Nolan A, et al. Obstructive airways disease with air trapping among firefighters exposed to World Trade Center dust. *Chest*. 137:566–74. [PubMed: 19820077]
84. Rundle AG, Vineis P, Ahsan H. Design options for molecular epidemiology research within cohort studies. *Cancer Epidemiol Biomarkers Prev*. 2005; 14:1899–907. [PubMed: 16103435]
85. Rosenberg L, Slone D, Shapiro S, et al. Breast cancer and alcoholic-beverage consumption. *Lancet*. 1982; 1:267–70. [PubMed: 6120284]
86. Van Berge-Landry HM, Bovbjerg DH, James GD. The reproducibility of ethnic differences in the proportional awake-sleep blood pressure decline among women. *Am J Hum Biol*. 2010; 22:325–9. [PubMed: 19844896]
87. Palmer IM, Schutte AE, Huisman HW. Ethnic and gender differences regarding the insulin-blood pressure relationship. *Diabetes Res Clin Pract*. 2009; 85:102–10. [PubMed: 19443068]
88. Naveed B, Weiden MD, Kwon S, et al. Metabolic Syndrome Biomarkers Predict Lung Function Impairment: A Nested Case-Control Study. *Am J Respir Crit Care Med*. 2011
89. Gude D, Naveed S. Comprehending trichotillomania. *Int J Trichology*. 2012; 4:100–1. [PubMed: 23180919]
90. Longo KA, Govek EK, Nolan A, et al. Pharmacologic inhibition of ghrelin receptor signaling is insulin sparing and promotes insulin sensitivity. *J Pharmacol Exp Ther*. 2011; 339:115–24. [PubMed: 21775475]
91. Chen JC, Schwartz J. Metabolic syndrome and inflammatory responses to long-term particulate air pollutants. *Environ Health Perspect*. 2008; 116:612–7. [PubMed: 18470293]
92. Lazarus R, Sparrow D, Weiss ST. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. *Eur Respir J*. 1998; 12:641–5. [PubMed: 9762793]
93. Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women's Heart and Health Study. *Diabetologia*. 2004; 47:195–203. [PubMed: 14704837]
94. Lin WY, Yao CA, Wang HC, Huang KC. Impaired lung function is associated with obesity and metabolic syndrome in adults. *Obesity (Silver Spring)*. 2006; 14:1654–61. [PubMed: 17030977]
95. Fimognari FL, Pasqualetti P, Moro L, et al. The association between metabolic syndrome and restrictive ventilatory dysfunction in older persons. *J Gerontol A Biol Sci Med Sci*. 2007; 62:760–5. [PubMed: 17634324]
96. Leone N, Courbon D, Thomas F, et al. Lung Function Impairment and Metabolic Syndrome: The Critical Role of Abdominal Obesity. *American Journal of Respiratory and Critical Care Medicine*. 2009; 179:509–16. [PubMed: 19136371]
97. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005; 112:2735–52. [PubMed: 16157765]
98. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med*. 2006; 23:469–80. [PubMed: 16681555]
99. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. *Cardiol Rev*. 2005; 13:322–7. [PubMed: 16708441]
100. Naveed S, Okoli K, Hollingsworth J, Kasmani R. Guillain-Barre syndrome as a paraneoplastic manifestation of small-cell carcinoma of lung. *South Med J*. 2010; 103:156–8. [PubMed: 20175250]

101. Siddiqi A, Khan DA, Khan FA, Naveed AK. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population. *Pak J Pharm Sci.* 2010; 23:417–22. [PubMed: 20884456]
102. Murph M, Mills GB. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. *Expert Rev Mol Med.* 2007; 9:1–18. [PubMed: 17935635]
103. Smyth SS, Cheng HY, Miriyala S, Panchatcharam M, Morris AJ. Roles of lysophosphatidic acid in cardiovascular physiology and disease. *Biochim Biophys Acta.* 2008; 1781:563–70. [PubMed: 18586114]
104. Rodriguez-Roisin R, Drakulovic M, Rodriguez DA, Roca J, Barbera JA, Wagner PD. Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity. *J Appl Physiol.* 2009; 106:1902–8. [PubMed: 19372303]
105. Liebow AA. Pulmonary emphysema with special reference to vascular changes. *Am Rev Respir Dis.* 1959; 80:67–93. [PubMed: 13670406]
106. King MS, Eisenberg R, Newman JH, et al. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. *N Engl J Med.* 2011; 365:222–30. [PubMed: 21774710]
107. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. An animal model of autoimmune emphysema. *Am J Respir Crit Care Med.* 2005; 171:734–42. [PubMed: 15563631]
108. Voelkel N, Taraseviciene-Stewart L. Emphysema: an autoimmune vascular disease? *Proc Am Thorac Soc.* 2005; 2:23–5. [PubMed: 16113465]
109. Zureik M, Benetos A, Neukirch C, et al. Reduced pulmonary function is associated with central arterial stiffness in men. *Am J Respir Crit Care Med.* 2001; 164:2181–5. [PubMed: 11751184]
110. Tockman MS, Pearson JD, Fleg JL, et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. *Am J Respir Crit Care Med.* 1995; 151:390–8. [PubMed: 7842197]
111. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J.* 2008; 32:962–9. [PubMed: 18579551]
112. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med.* 2004; 350:1387–97. [PubMed: 15070788]
113. Elbers PW, Ince C. Mechanisms of critical illness--classifying microcirculatory flow abnormalities in distributive shock. *Crit Care.* 2006; 10:221. [PubMed: 16879732]
114. Cirillo DJ, Agrawal Y, Cassano PA. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. *Am J Epidemiol.* 2002; 155:842–8. [PubMed: 11978588]
115. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. *Thorax.* 2006; 61:23–8. [PubMed: 16143583]
116. Yuditskaya S, Tumblin A, Hoehn GT, et al. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. *Blood.* 2009; 113:1122–8. [PubMed: 19023114]
117. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2011; 183:1187–92. [PubMed: 21216880]
118. Vulcano M, Struyf S, Scapini P, et al. Unique regulation of CCL18 production by maturing dendritic cells. *J Immunol.* 2003; 170:3843–9. [PubMed: 12646652]
119. Azzaoui I, Yahia SA, Chang Y, et al. CCL18 differentiates dendritic cells in tolerogenic cells able to prime regulatory T cells in healthy subjects. *Blood.* 2011; 118:3549–58. [PubMed: 21803856]
120. Salvi S, Blomberg A, Rudell B, et al. Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. *Am J Respir Crit Care Med.* 1999; 159:702–9. [PubMed: 10051240]
121. Mills NL, Tornqvist H, Gonzalez MC, et al. Ischemic and thrombotic effects of dilute diesel-exhaust inhalation in men with coronary heart disease. *N Engl J Med.* 2007; 357:1075–82. [PubMed: 17855668]
122. Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. *N Engl J Med.* 2012; 367:913–21. [PubMed: 22938715]

123. Nakanishi R, Rana JS, Shalev A, et al. Mortality Risk as a Function of the Ratio of Pulmonary Trunk to Ascending Aorta Diameter In Patients With Suspected Coronary Artery Disease. *Am J Cardiol.* 2013
124. Truong QA, Massaro JM, Rogers IS, et al. Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study. *Circ Cardiovasc Imaging.* 2012; 5:147–54. [PubMed: 22178898]
125. Rastogi A, Tan SH, Banerjee S, et al. ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. *Monoclon Antib Immunodiagn Immunother.* 2014; 33:201–8. [PubMed: 25170998]
126. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. *PLoS Med.* 2008; 5:e93. [PubMed: 18447576]
127. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. *Cardiovasc Res.* 2003; 59:812–23. [PubMed: 14553821]
128. Death AK, Nakhla S, McGrath KC, et al. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. *J Am Coll Cardiol.* 2002; 39:1943–50. [PubMed: 12084592]
129. Banauch GI, Brantly M, Izbicki G, et al. Accelerated spirometric decline in New York City firefighters with alpha-1 antitrypsin deficiency. *Chest.* 2010; 138:1116–24. [PubMed: 20634282]
130. Banauch GI, Brantly M, Izbicki G, et al. Accelerated spirometric decline in New York City firefighters with alpha-1 antitrypsin deficiency. *Chest.* 138:1116–24. [PubMed: 20634282]
131. Daroux M, Prevost G, Maillard-Lefebvre H, et al. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. *Diabetes Metab.* 2010; 36:1–10. [PubMed: 19932633]
132. Tekabe Y, Luma J, Einstein AJ, et al. A novel monoclonal antibody for RAGE-directed imaging identifies accelerated atherosclerosis in diabetes. *J Nucl Med.* 2010; 51:92–7. [PubMed: 20008983]
133. Spiekerkoetter E, Guignabert C, de Jesus Perez V, et al. S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4. *Circ Res.* 2009; 105:639–47. 13 p following 47. [PubMed: 19713532]
134. Suzuki R, Miyazaki Y, Takagi K, Torii K, Taniguchi H. Matrix metalloproteinases in the pathogenesis of asthma and COPD: implications for therapy. *Treat Respir Med.* 2004; 3:17–27. [PubMed: 15174890]
135. Imai K, Dalal SS, Chen ES, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. *Am J Respir Crit Care Med.* 2001; 163:786–91. [PubMed: 11254539]
136. Geraghty P, Dabo AJ, D'Armiento J. TLR4 protein contributes to cigarette smoke-induced matrix metalloproteinase-1 (MMP-1) expression in chronic obstructive pulmonary disease. *J Biol Chem.* 2011; 286:30211–8. [PubMed: 21730072]
137. Vandenbroucke RE, Dejonckheere E, Libert C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? *Eur Respir J.* 38:1200–14. [PubMed: 21659416]
138. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. *Cancer Metastasis Rev.* 2007; 26:717–24. [PubMed: 17717634]
139. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. *Thorax.* 2006; 61:259–66. [PubMed: 16227332]
140. Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. *Hum Mol Genet.* 2002; 11:569–76. [PubMed: 11875051]
141. Seabrook JM, Nolan PL. The vascular interaction of noradrenaline and 5-hydroxytryptamine. *Eur J Pharmacol.* 1983; 89:131–5. [PubMed: 6602711]
142. Bu DX, Rai V, Shen X, et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. *Circ Res.* 2010; 106:1040–51. [PubMed: 20133903]

143. D'Armiento JM, Goldklang MP, Hardigan AA, et al. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. *PLoS One*. 2013; 8:e56352. [PubMed: 23441181]
144. Posthumus MD, Limburg PC, Westra J, et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. *Rheumatology (Oxford)*. 1999; 38:1081–7. [PubMed: 10556259]
145. Seibold MA, Donnelly S, Solon M, et al. Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit. *J Allergy Clin Immunol*. 2008; 122:944–50. e3. [PubMed: 18845328]
146. Aminuddin F, Akhabir L, Stefanowicz D, et al. Genetic association between human chitinases and lung function in COPD. *Hum Genet*. 2012; 131:1105–14. [PubMed: 22200767]
147. Araujo AC, Souto-Padron T, de Souza W. Cytochemical localization of carbohydrate residues in microfilariae of *Wuchereria bancrofti* and *Brugia malayi*. *J Histochem Cytochem*. 1993; 41:571–8. [PubMed: 8450196]
148. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. *Annu Rev Microbiol*. 1994; 48:471–97. [PubMed: 7826015]
149. Fuhrman JA, Piessens WF. Chitin synthesis and sheath morphogenesis in *Brugia malayi* microfilariae. *Mol Biochem Parasitol*. 1985; 17:93–104. [PubMed: 3932852]
150. Neville AC, Parry DA, Woodhead-Galloway J. The chitin crystallite in arthropod cuticle. *J Cell Sci*. 1976; 21:73–82. [PubMed: 932111]
151. Shahabuddin M, Kaslow DC. Plasmodium: parasite chitinase and its role in malaria transmission. *Exp Parasitol*. 1994; 79:85–8. [PubMed: 7914174]
152. Di Rosa M, Musumeci M, Scuto A, Musumeci S, Malaguarnera L. Effect of interferon-gamma, interleukin-10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages. *Clin Chem Lab Med*. 2005; 43:499–502. [PubMed: 15899671]
153. Malaguarnera L, Musumeci M, Di Rosa M, Scuto A, Musumeci S. Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. *J Clin Lab Anal*. 2005; 19:128–32. [PubMed: 15900564]
154. Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JM. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. *J Biol Chem*. 1995; 270:2198–202. [PubMed: 7836450]
155. van Eijk M, van Roomen CP, Renkema GH, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. *Int Immunol*. 2005; 17:1505–12. [PubMed: 16214810]
156. Agapov E, Battaile JT, Tidwell R, et al. Macrophage chitinase 1 stratifies chronic obstructive lung disease. *Am J Respir Cell Mol Biol*. 2009; 41:379–84. [PubMed: 19491341]
157. Letuve S, Kozhich A, Humbles A, et al. Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. *Am J Pathol*. 2010; 176:638–49. [PubMed: 20042671]
158. Postma DS, Bleecker ER, Amelung PJ, et al. Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. *N Engl J Med*. 1995; 333:894–900. [PubMed: 7666875]
159. Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. *Eur Respir J*. 2000; 16:609–14. [PubMed: 11106200]
160. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. *N Engl J Med*. 1991; 325:1067–71. [PubMed: 1891008]
161. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *N Engl J Med*. 2011; 364:1005–15. [PubMed: 21410369]
162. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. *Ann Intern Med*. 2011; 154:573–82. [PubMed: 21536936]

163. Renkema TE, Kerstjens HA, Schouten JP, Vonk JM, Koeter GH, Postma DS. The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. *Clin Exp Allergy*. 1998; 28:1210–8. [PubMed: 9824387]
164. Farfel M, DiGrande L, Brackbill R, et al. An overview of 9/11 experiences and respiratory and mental health conditions among World Trade Center Health Registry enrollees. *J Urban Health*. 2008; 85:880–909. [PubMed: 18785012]
165. Kleinman EJ, Cucco RA, Martinez C, et al. Pulmonary function in a cohort of New York City Police Department emergency responders since the 2001 World Trade Center disaster. *J Occup Environ Med*. 2011; 53:618–26. [PubMed: 21654431]
166. Salzman SH, Moosavy FM, Miskoff JA, Friedmann P, Fried G, Rosen MJ. Early respiratory abnormalities in emergency services police officers at the World Trade Center site. *J Occup Environ Med*. 2004; 46:113–22. [PubMed: 14767214]
167. Friedman SM, Maslow CB, Reibman J, et al. Case-control study of lung function in World Trade Center Health Registry area residents and workers. *Am J Respir Crit Care Med*. 2011; 184:582–9. [PubMed: 21642248]
168. Kazeros A, Maa MT, Patrawalla P, et al. Elevated peripheral eosinophils are associated with new-onset and persistent wheeze and airflow obstruction in world trade center-exposed individuals. *J Asthma*. 2013; 50:25–32. [PubMed: 23227974]
169. Skloot G, Goldman M, Fischler D, et al. Respiratory symptoms and physiologic assessment of ironworkers at the World Trade Center disaster site. *Chest*. 2004; 125:1248–55. [PubMed: 15078731]
170. Mann JM, Sha KK, Kline G, Breuer FU, Miller A. World Trade Center dyspnea: bronchiolitis obliterans with functional improvement: a case report. *Am J Ind Med*. 2005; 48:225–9. [PubMed: 16094618]
171. Oppenheimer BW, Goldring RM, Herberg ME, et al. Distal airway function in symptomatic subjects with normal spirometry following World Trade Center dust exposure. *Chest*. 2007; 132:1275–82. [PubMed: 17890470]
172. Mendelson DS, Roggeveen M, Levin SM, Herbert R, de la Hoz RE. Air trapping detected on end-expiratory high-resolution computed tomography in symptomatic World Trade Center rescue and recovery workers. *J Occup Environ Med*. 2007; 49:840–5. [PubMed: 17693781]





Figure 1. WTC-FDNY Biomarker Timeline and development of Nested Case- Cohort Control Study Design

Summary of phenotyping that was done on the cohort and case susceptible and resistant to WTC-LI are shown in the inclusion criteria to develop the baseline cohort. Overlapping of cohort control with cases susceptible and resistant to WTC-LI is highlighted in the dashed red circle.

A. Biomarkers of Susceptibility to WTC-LI



B. Biomarkers of Resistance to WTC-LI




Figure 2. Overview of Biomarkers predicting WTC-LI as defined by FEV₁ < LLN
A. Utilizing a Susceptible case-cohort control design **B.** Utilizing a resistant case-cohort control design. *Represents relative risk †Not previously published

Table 1
Overview of the Spirometric and Radiographic Findings in the WTC Exposed Cohorts

Source	Phenotype	Study Cohort	Findings	References
PFT	OAD	FDNY, Iron workers, NYPD, rescue-recovery workers and volunteers	Decreased FEV ₁ , Decreased FEV ₁ /FVC	39,41-44,46,47,50,51,61,67,164-168
	BD response	FDNY	Reversible abnormality on post-BD spirometry*	67
	MCT	FDNY	Bronchial hyperactivity†	31,67
	Pseudo-restrictive	FDNY, iron workers	FEV ₁ /FVC<LLN, FVC<LLN, TLC LLN	33,169
	Restrictive	FDNY, NYPD, Community workers		24,27,81,170
Radiographic	Small Airways	FDNY, Community workers	FVC<LLN, FEV ₁ /FVC and TLC LLN	67,81,171
	Emphysema/COPD	FDNY, Community Workers		38,67
	BWT	FDNY		67,81
	Air trapping	FDNY, NYPD, Technical and Construction Workers		67,81,172

Abbreviations: PFT: pulmonary function test; OAD: obstructive airways disease; BD: bronchodilator; BWT: Bronchial wall thickening; FDNY: Fire Department of New York; FEV₁: forced expiratory volume over 1 second; FVC: forced vital capacity; LLN: Lower limit of normal; TLC: Total lung capacity

* post-BD FEV₁ 12% change from pre-BD and improvement of FEV₁ 200mL

† Methacholine PC20 8mg/mL, <16mg/mL